Dianthus officer plans sale of 23,124 shares

Dianthus Therapeutics, Inc. (DNTH) is the issuer for a notice filed by officer Simrat Randhawa under Rule 144 to potentially sell up to 23,124 shares of common stock through Morgan Stanley Smith Barney LLC on or after 09/01/2026 on NASDAQ.

Rhea-AI Filing Summary

Dianthus Therapeutics, Inc. (DNTH) is the issuer for a notice filed by officer Simrat Randhawa under Rule 144 to potentially sell up to 23,124 shares of common stock through Morgan Stanley Smith Barney LLC on or after 09/01/2026 on NASDAQ. The shares are to be acquired via exercise of stock options for cash from the issuer. The notice lists an aggregate market value of $2,442,125.64 for the securities covered and indicates 55,934,378 shares of common stock outstanding.

Key Figures

Shares to be sold: 23,124 shares of common stock Aggregate market value: $2,442,125.64 Shares outstanding: 55,934,378 shares +1 more

4 metrics

Shares to be sold 23,124 shares of common stock Maximum number of shares covered by the Rule 144 notice

Aggregate market value $2,442,125.64 Aggregate market value of the 23,124 shares covered

Shares outstanding 55,934,378 shares Number of Dianthus Therapeutics, Inc. common shares outstanding

Proposed sale date 09/01/2026 Proposed date for sales under the Form 144

Key Terms

Rule 144, aggregate market value, Exercise of Stock Options, Securities To Be Sold

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

aggregate market value financial

"Common | Morgan Stanley ... | 23124 | 2442125.64 | 55934378 | 09/01/2026"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Exercise of Stock Options financial

"Common | 09/01/2026 | Exercise of Stock Options | Issuer |"

Securities To Be Sold regulatory

"144: Securities To Be Sold Common | 09/01/2026 | Exercise of Stock Options"

FAQ

What does the Form 144 filed for DNTH disclose?

It discloses that officer Simrat Randhawa intends, under Rule 144, to potentially sell up to 23,124 shares of Dianthus Therapeutics, Inc. common stock, to be acquired by exercising stock options for cash and sold through Morgan Stanley Smith Barney LLC on or after 09/01/2026.

How many DNTH shares are covered by Simrat Randhawa’s Form 144?

The notice covers up to 23,124 shares of Dianthus Therapeutics, Inc. common stock. These shares are associated with an aggregate market value of $2,442,125.64 as reported in the filing.

What is the reported aggregate market value of the DNTH shares on the Form 144?

The filing reports an aggregate market value of $2,442,125.64 for the 23,124 shares of Dianthus Therapeutics, Inc. common stock that may be sold under Rule 144.

How will the DNTH shares be obtained for sale under this Form 144?

The 23,124 shares of Dianthus Therapeutics, Inc. common stock are to be obtained through the exercise of stock options with the issuer for cash, as specified in the Form 144 before any potential resale.

What is the number of DNTH shares outstanding referenced in the Form 144?

The Form 144 references 55,934,378 shares of Dianthus Therapeutics, Inc. common stock outstanding. This figure provides context and is not the amount being sold.

On which market and from what date may the DNTH shares be sold under this Form 144?

The shares may be sold on NASDAQ with a proposed sale date of 09/01/2026, according to the information provided in the Form 144 for Dianthus Therapeutics, Inc.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/01/2026 - 04:49 PM Accepted by SEC EDGAR 09/01/2026 - 04:49 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001992260
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	DIANTHUS THERAPEUTICS INC
SEC File Number	001-38541
Address of Issuer	7 Times Square, 43rd Floor New York NEW YORK 10036
Phone	9299994055
Name of Person for Whose Account the Securities are To Be Sold	SIMRAT RANDHAWA
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	23124	2442125.64	55934378	09/01/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/01/2026	Exercise of Stock Options	Issuer			23124	09/01/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/01/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/14/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Simrat Randhawa
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)